pragma.vision Technology observatory & strategic foresight

Verification register Bio, Health & Neuro

Readiness verdict

NewLimit Liver Reprogramming Medicine (LNP-RNA transcription factors)

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-08-20
Revision
1
Method
v1.3.0

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Emerging

Primary summary from verified readiness

Confidence
75% · stale
Computed at
2026-08-20T10:54:51.286677+00:00
Claimed
30

Public ambition and stated capability

Reported
30

Observed practitioner reporting

Verified
28

Independently supported evidence

Gap
+2

Claimed leads verified

Evidence strength Strong

Decision

What the current evidence supports

Human editorial judgment · 2026-08-20

Wait for stronger evidence

Why
A $435M raise and a credible LNP-RNA platform make this a serious player, but it is preclinical with clinic entry still ~a year out and no published human-relevant efficacy numbers — strong momentum, weak evidence
Next
Monitor for the IND filing and the planned ~2027 first-in-human liver trial; require peer-reviewed quantified preclinical efficacy (not payload-engineering deltas) before upgrading from watch status

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
12
Tier 1
0
Tier 2
4
Tier 3
8
Supports
4
Contradicts
2
Context
6
Latest observed
2026-06-01

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

  1. 2026-07-19 Reading moved from emerging to emerging.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.